---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-009202"
form_type: "8-K"
ticker: "SRZN"
cik: "0001824893"
company_name: "Surrozen, Inc./DE"
filed_at: "2023-03-22T23:59:59+00:00"
generated_at: "2026-06-17T21:35:56.232585+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Surrozen reports FY2022 net loss of $36M; cash runway into H2 2024

## Summary
- Net loss for FY2022 was $36.0M vs $54.6M in FY2021; collaboration revenue $12.5M from Boehringer Ingelheim deal.
- Cash, equivalents and marketable securities $75.8M as of Dec 31, 2022, down from $123.5M a year ago.
- Restructuring reduces operating expenses by ~15% in 2023; cash runway extends into second half of 2024.
- SZN-043 Ph1a enrolled first chronic liver disease patient, data expected end 2023; SZN-1326 Ph1a to reinitiate mid-2023.
- Repurchased 5.38M shares and 1.31M warrants from Consonance for ~$2.7M; Consonance no longer holds shares.

## SEC filing metadata
- accession: 0000950170-23-009202
- form_type: 8-K
- ticker: SRZN
- cik: 0001824893
- company_name: Surrozen, Inc./DE
- filed_at: 2023-03-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1824893/000095017023009202/0000950170-23-009202-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1824893/000095017023009202/srzn-20230322.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-009202
- JSON: https://secwatch.observer/filing/0000950170-23-009202.json
- Plain text: https://secwatch.observer/filing/0000950170-23-009202.txt

## Key facts
- Earnings Releases
  Surrozen, Inc./DE reported the year ended December 31, 2022 results: revenue $12.5 million.
  - Period: the year ended December 31, 2022
  - Revenue: $12.5 million
  - Result: reported results
  source text: Collaboration and License Revenue for the fourth quarter and year ended December 31, 2022, was $12.5 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1824893/000095017023009202/0000950170-23-009202-index.htm
- Earnings Releases
  Surrozen, Inc./DE reported the fourth quarter ended December 31, 2022 results: revenue $12.5 million.
  - Period: the fourth quarter ended December 31, 2022
  - Revenue: $12.5 million
  - Result: reported results
  source text: Collaboration and License Revenue for the fourth quarter and year ended December 31, 2022, was $12.5 million
  evidence_url: https://www.sec.gov/Archives/edgar/data/1824893/000095017023009202/0000950170-23-009202-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.